Somatotropin Biosimilar Insight

DelveInsight’s, “Somatropin – Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Somatropin Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Somatropin Understanding

Somatropin: Overview

Somatropin is used to treat growth failure in children and adults who lack natural growth hormone. This includes people with short stature due to Noonan syndrome, Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes. hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.

Somatropin Biosimilars: Drugs Chapters

This segment of the Somatropin report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Somatropin Biosimilars: Marketed Drugs

  • Omnitrope: Sandoz

Omnitrope (somatropin [rDNA origin] injection) is a form of human growth hormone used to treat growth failure in children and adults who lack natural growth hormone, and in those with chronic kidney failure, Noonan syndrome, Turner syndrome, short stature at birth with no catch-up growth, and other causes.

Further product details are provided in the report……..

Somatropin Biosimilars: Emerging Drugs


  • Somatropin beta-1b biosimilar: Harvest Moon Pharmaceuticals

Harvest Moon Pharmaceuticals is developing Somatropin beta-1b biosimilar for the treatment of Multiple sclerosis.

Further product details are provided in the report……..

Somatropin: Therapeutic Assessment

This segment of the report provides insights about the different Somatropin biosimilars segregated based on following parameters that define the scope of the report, such as:


  • Major Players in Somatropin

There are approx. 10+ key companies which are developing the therapies for Somatropin.


  • Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Somatropin pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Typet

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Somatropin: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Somatropin biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatropin biosimilar drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Somatropin R&D. The therapies under development are focused on novel approaches to treat/improve Somatropin.
  • Somatropin Biosimilars Report Insights
  • Somatropin Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs

Somatropin Biosimilar Report Assessment

  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Somatropin Biosimilars?
  • How many Somatropin biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Somatropin biosimilars therapeutics?
  • What are the clinical studies going on for Somatropin biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • USV
  • Sedico
  • Sandoz
  • rEVO Biologics
  • Reliance Life Sciences
  • Polus BioPharm
  • Pfizer
  • Inbiopro Solutions
  • Harvest Moon Pharmaceuticals
  • Cristalia
  • CinnaGen
  • Biosidus
  • BioPartners
  • Bio-Ker
  • AryaTinaGene
  • Amega Biotech

Key Products

  • Human growth hormone biosimilar
  • Somatropin (rDNA origin)
  • Omnitrope
  • Human growth hormone
  • R-TPR-007
  • SomatoRel
  • PDP805
  • Genotonorm
  • IBPB 003HH
  • Somatotropin biosimilar
  • • r-hGH Cristalia
  • Cinnatropin
  • Growmax
  • Valtropin
  • Recombinant somatropin
  • Somatropin biosimilar
  • Recombinant human growth hormone

 

1. Key Insights

2. Somatropin Biosimilars: Snapshot

3. Executive Summary

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. Somatropin (Reference Product: Genotropin)

5.1. Drug Profile

5.2. Product Overview

5.3. Regulatory Approvals and Launch

5.4. Indications

5.5. Mechanism of Action

5.6. Dosage and Administration

5.7. Dosage and Strengths

5.8. Dose Modification

5.9. Route of Synthesis

5.10. Pharmacology

5.11. Pharmacodynamics

5.12. Pharmacokinetics

5.13. Adverse Reactions

5.14. Product Snapshot

5.15. Development Milestones

6. Research and Development

6.1. Clinical Trials Information

6.2. Safety and Efficacy

7. Genotropin Biosimilar: Emerging Opportunities

*More variants of Somatropin would be added in the final report

8. Somatropin: Biosimilars Assessment

8.1. Assessment by Product Type

8.2. Assessment by Route of Administration

8.3. Assessment by Molecule type

8.4. Sales Assessment

9. Somatropin Biosimilars Profiles: By Company

9.1.1. Sandoz

9.1.1.1. Omnitrope: Sandoz

9.1.1.1.1. Product Information

9.1.1.1.2. Research and Development

9.1.1.1.3. Other Development Activities

9.1.1.1.4. General Description Table

9.1.2. Pfizer

9.1.2.1. Genotonorm: Pfizer

9.1.2.1.1. Product Information

9.1.2.1.2. Research and Development

9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

*More Companies and products would be added in the final report

10. Somatropin Biosimilars: Comparative Landscape: By Company

11. Somatropin Biosimilars: Competitive Landscape

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

 Table 1 Total Products for Somatropin

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for Somatropin

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

  • Tags:
  • Somatotropin
  • Somatotropin MOA
  • Somatotropin Mechanism of Action
  • What is Somatotropin
  • Somatotropin Genotropin
  • Somatotropin Generic
  • Somatotropin Biosimilars approval
  • Somatotropin Biosimilars companies
  • Somatotropin biosimilars
  • Somatotropin biosimilar guidelines

Forward to Friend

Need A Quote